Incidental gallbladder cancer (found after cholecystectomy): lines of therapy
3 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 3 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Tis or T1a with a clear cystic duct margin | No further surgery; the simple cholecystectomy is treatment enough. | - | ||
| All comers | T1b, T2 or T3, no metastases | Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after. | AHPBA consensus statement (HPB 2015); Soreide systematic review (Br J Surg 2019) | 92 | |
| All comers | Residual disease found on interval imaging or at re-operation | Systemic treatment as for advanced gallbladder cancer. | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.